Mittie Doyle serves as Executive at Avalo Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Mittie Doyle has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Dec 10, 2025 involved selling 1,013 shares valued at $4.2K.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Dec 10, 2025 | AVTX | $4.2K | Payment | 1,013 | $4.10 | Discretionary |
Mittie Doyle currently holds 3,622 shares of Avalo Therapeutics, Inc. (AVTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Mittie Doyle has been a net neutral trader of AVTX stock. They have purchased $0 and sold $0 worth of shares.
Mittie Doyle's most recent insider trade was on Dec 10, 2025, when they sold 1,013 shares at $4.10 per share.
Get notified when new Form 4 filings are submitted